Nerviano, Italy – Shanghai, China 1 August 2025 — Nerviano Medical Sciences Srl (NMS Srl or NMS), a clinical stage biopharmaceutical leader in oncology innovation, announced today the expansion of its presence in Asia with the establishment of Nerviano Medical Sciences (Shanghai) Ltd.
The new subsidiary, incorporated in Shanghai, places NMS in one of the world’s fastest-growing hubs for biotechnology and pharmaceutical innovation. With strong government backing, increased investment, and a deep focus on R&D, Shanghai is rapidly becoming a powerhouse for life sciences in Asia and beyond.
“I am thrilled that NMS is expanding its global reach into China, following the successful launch of our U.S. affiliate in 2023,” said Hugues Dolgos, Pharm.D, CEO of NMS Group and NMS Srl. “We’ve already assembled a clinical team to support key clinical trials in China, along with a business development team focused on leveraging the dynamic Asian ecosystem, fostering innovation, and building strategic partnerships to accelerate our clinical pipeline and ADC (antibody-drug conjugate) portfolio.”
Leading the new subsidiary is Dadong Li, Ph.D., CEO of NMS Shanghai, who added, “I’m honored to open our first office in China and look forward to submitting our first IND in China to enroll patients in 2026 for our highly innovative assets. I’m especially proud to welcome Dr. Yaling Huang, a talented physician-scientist, as Global Clinical Lead—demonstrating our commitment to delivering breakthrough cancer treatments to patients in China and around the world where unmet needs remain.”
With this milestone, NMS reinforces its mission to bring forward life-changing oncology therapies on a global scale.
